Scarica l'app Stockscreener
10.14
148.54%
6.045
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.10
Aprire:
$11.59
Volume 24 ore:
81.47M
Relative Volume:
39.36
Capitalizzazione di mercato:
$689.50M
Reddito:
-
Utile/perdita netta:
$-117.81M
Rapporto P/E:
-5.3963
EPS:
-1.88
Flusso di cassa netto:
$74.30M
1 W Prestazione:
+132.12%
1M Prestazione:
+149.14%
6M Prestazione:
+48.33%
1 anno Prestazione:
+147.93%
Intervallo 1D:
$9.19
$12.10
Intervallo di 1 settimana:
$4.055
$12.10
Portata 52W:
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
Nome
Omeros Corporation
Settore
Industria
Telefono
206-676-5000
Indirizzo
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Confronta OMER con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
10.13 | 279.03M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.88 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.27 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.90 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
810.78 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.92 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2022-12-08 | Downgrade | UBS | Buy → Neutral |
| 2022-11-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Downgrade | Maxim Group | Buy → Hold |
| 2021-10-01 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-09-27 | Iniziato | JP Morgan | Neutral |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-08-21 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-14 | Reiterato | Maxim Group | Buy |
| 2019-05-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-03-05 | Downgrade | Needham | Buy → Hold |
| 2017-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2017-05-11 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Reiterato | Maxim Group | Buy |
| 2017-03-17 | Reiterato | Needham | Buy |
| 2016-11-16 | Reiterato | Wedbush | Outperform |
| 2016-11-10 | Reiterato | Needham | Buy |
| 2016-08-10 | Reiterato | Maxim Group | Buy |
| 2016-06-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-02 | Reiterato | Needham | Buy |
| 2016-02-29 | Reiterato | Wedbush | Outperform |
| 2015-11-11 | Reiterato | Needham | Buy |
| 2015-08-18 | Reiterato | WBB Securities | Strong Buy |
| 2015-08-10 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Omeros Corporation Borsa (OMER) Ultime notizie
Omeros Stock (OMER) Surges 140% on Novo Nordisk (NVO) Deal - TipRanks
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next? - ts2.tech
Omeros price target raised to $20 from $9 at H.C. Wainwright - TipRanks
OMER: Analyst Jason Kolbert Maintains 'Buy' Rating and $36 Targe - GuruFocus
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push - Reuters
Omeros rockets on news of deal with Novo Nordisk - The Pharma Letter
Omeros Corporation (OMER) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know - ts2.tech
Omeros (OMER) Stock Skyrockets Following $2.1B Deal with Novo No - GuruFocus
Will Omeros Corp Bounce Back? - StocksToTrade
Novo Buys Omeros Rare-Disease Drug for Up to $2.1 Billion - Bloomberg.com
Omeros (OMER) Shares Surge 124% Following New License Agreement - GuruFocus
Novo Nordisk acquires zaltenibart drug candidate from Omeros - MarketScreener
Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug - MarketScreener
Omeros Signs Major Deal with Novo Nordisk - TipRanks
Novo Nordisk pens $2.1B deal for Omeros’ stalled PNH drug - Fierce Biotech
Omeros stock spikes on Novo licensing deal (OMER:NASDAQ) - Seeking Alpha
Omeros stock soars after $2.1 billion deal with Novo Nordisk - Investing.com
Novo Nordisk and Omeros announce asset purchase and license - GlobeNewswire
Quantitative breakdown of Omeros Corporation recent moveJuly 2025 Trade Ideas & Daily Chart Pattern Signal Reports - newser.com
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - Stocktwits
Omeros Corporation stock outlook for YEARQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
Wealth Enhancement Advisory Services LLC Has $84,000 Stock Holdings in Omeros Corporation $OMER - Defense World
Can Omeros Corporation stock sustain institutional interestBull Run & Capital Efficient Trading Techniques - newser.com
Omeros (NASDAQ:OMER) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
What institutional flow reveals about Omeros CorporationTrade Exit Report & Advanced Swing Trade Entry Plans - newser.com
Lobbying Update: $30,000 of OMEROS CORPORATION lobbying was just disclosed - Quiver Quantitative
Omeros surges 22% on clarity for BLA resubmission for narsoplimab - MSN
How to build a dashboard for Omeros Corporation stockWeekly Earnings Recap & Expert Approved Trade Ideas - newser.com
Retail investors who hold 53% of Omeros Corporation (NASDAQ:OMER) gained 10%, institutions profited as well - simplywall.st
Mydriasis Market: Epidemiology, Therapies, and Key Players include Théa Laboratories, Omeros Corporation, Ocuphire Pharma. - Barchart.com
Intraday pattern recognizer results for Omeros CorporationJuly 2025 Patterns & Free Community Consensus Stock Picks - newser.com
Omeros Corporation stock trend forecast2025 Major Catalysts & Real-Time Sentiment Analysis - newser.com
What moving averages say about Omeros CorporationMarket Performance Recap & Real-Time Stock Price Movement Reports - newser.com
Is Omeros Corporation a good long term investmentInsider Buying Signals & Build Wealth With Strategy - earlytimes.in
Using RSI to spot recovery in Omeros CorporationAnalyst Downgrade & Community Verified Watchlist Alerts - newser.com
Omeros Corporation to acquire $80.5 million of its convertible senior notes due 2026 - MSN
Omeros Corporation Completes Promising Phase 2 Study on OMS906 for PNH - TipRanks
What analysts say about Omeros Corporation stockTechnical Breakout Signals & Receive Monthly Expert Trading Blueprints - earlytimes.in
Omeros Corporation Azioni (OMER) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.74%
0.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):